תאריך רישום: July 29, 2018

מסלול הגשה: מולקולה חדשה

יצרן: JANSSEN PHARMACEUTICA N.V, BELGIUM

בעל רישום: J-C HEALTH CARE LTD

J04AK05 :ATC Code

4.1 Therapeutic indications SIRTURO is indicated for use as part of an appropriate combination regimen for pulmonary multidrug-resistant tuberculosis (MDR-TB) in adult patients when an effective treatment regimen cannot otherwise be composed for reasons of resistance or tolerability (see sections 4.2, 4.4 and 5.1). Consideration should be given to official guidance on the appropriate use of antibacterial agents.

תאריך רישום: May 30, 2007

מסלול הגשה: תכשיר גנרי

יצרן: NOVOCOL PHARMACEUTICAL OF CANADA INC

בעל רישום: HENRY SCHEIN SHVADENT (2009 ) LTD

N01BB02 :ATC Code

Therapeutic indications: For the production of local anaesthesia by nerve block or infiltration technique. Dental infiltration injection, dental nerve block.

תאריך רישום: June 5, 2008

מסלול הגשה: תכשיר גנרי

יצרן: PERRIGO NEW YORK INC, USA

בעל רישום: PADAGIS ISRAEL AGENCIES LTD, ISRAEL

D01AE14 :ATC Code

תאריך רישום: June 28, 2018

מסלול הגשה: תכשיר גנרי

יצרן: TOWA PHARMACEUTICAL EUROPE, S.L. , SPAIN

בעל רישום: K.S.KIM INTERNATIONAL (SK- PHARMA) LTD., ISRAEL

A02BC05 :ATC Code

תאריך רישום: June 2, 2018

מסלול הגשה: מולקולה חדשה

יצרן: PATHEON INC., CANADA

בעל רישום: NEOPHARM LTD, ISRAEL

L01XX55 :ATC Code

1 INDICATIONS AND USAGE 1.1 Maintenance Treatment of Recurrent Ovarian Cancer Rubraca is indicated for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy

תאריך רישום: December 28, 2016

מסלול הגשה: תכשיר גנרי

יצרן: FRESENIUS KABI NORGE AS, NORWAY

בעל רישום: CURE MEDICAL & TECHNICAL SUPPLY

B05XA31 :ATC Code

4.1 Therapeutic indications To meet basal to moderately increased requirements of trace elements in intravenous nutrition.